Business Context and Reporting Period
Company: eFoodSafety.com, Inc. (Note: Request metadata listed "Pharmacyte Biotech, Inc.", but the filing text identifies the issuer as eFoodSafety.com, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: January 31, 2009
Business Overview: The Company operates through subsidiaries including KNOCK-OUT (food-grade formulations), MEDELITE (medical products), CINNERGEN (nutritional supplements), and others. Approximately 84% of revenues for the nine months ended January 31, 2009, were derived from the sale of Cinnergen products.
Key Financial Metrics
| Metric | Three Months Ended Jan 31, 2009 | Nine Months Ended Jan 31, 2009 | Nine Months Ended Jan 31, 2008 |
|---|---|---|---|
| Revenues | $130,367 | $580,023 | $958,549 |
| Gross Profit | $99,094 | $413,554 | $743,281 |
| Gross Margin % | 76% | 71% | 77% |
| Net Loss | $(870,587) | $(1,827,586) | $(2,726,575) |
| Loss Per Share (Basic) | $(0.00) | $(0.01) | $(0.02) |
| Cash and Equivalents (End of Period) | $958,577 (as of Jan 31, 2009) | ||
| Working Capital | |||
| Total Assets | $5,652,296 (as of Jan 31, 2009) | ||
| Total Liabilities |
Liquidity: Cash decreased by $554,964 during the nine-month period. Net cash used in operating activities was $540,184. The Company reported a working capital of $2,257,304 as of January 31, 2009.
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 57% for the quarter and 39% year-to-date compared to the prior year. Management attributes this to reduced advertising and promotion activities.
- Expense Reduction: Consulting fees dropped significantly from $898,717 (quarterly 2008) to $516,213 (quarterly 2009). Research and development expenses also decreased.
- Bad Debt Provision: General and administrative expenses increased due to a $275,000 bad debt expense related to anticipated returns on Cinnergen sales.
- Stock Issuances: The Company issued 3,600,000 shares for services valued at $126,000 during the quarter and 250,000 shares for services valued at $89,000 in the first six months of the fiscal year.
Outlook, Risks, and Unusual Items
- Going Concern: The filing states there is "substantial doubt" about the Company's ability to continue as a going concern due to recurring losses and the need for continued financial support from directors and stockholders.
- Subsequent Events:
- Completed a share exchange to acquire 100% of Freedom2 Holdings, Inc. (tattoo ink technology) on March 2, 2009, issuing 48,205,000 shares.
- Restructured the marketing agreement for PurEffect(TM), transferring rights to Charlston Kentrist 41 Direct, Inc. in exchange for stock, warrants, and royalties.
- Concentration Risk: The Company relies heavily on the Cinnergen product (84% of revenue) and four major customers (70% of Cinnergen sales).
- Capital Needs: The Company expects to need additional capital to fund operations and expansion. Failure to raise capital could result in curtailment of business operations.
Investor Verification Checklist
- Going Concern Status: Verify the Company's ability to secure funding to cover operating deficits beyond the next six months.
- Revenue Concentration: Assess the risk associated with 84% of revenue coming from a single product line (Cinnergen) and 70% of that from four customers.
- Subsequent Acquisitions: Review the financial impact and integration plans for the Freedom2 Holdings acquisition and the PurEffect restructuring.
- Stock Dilution: Monitor the impact of recent and potential future stock issuances for services and acquisitions on existing shareholders.
- Bad Debt Exposure: Confirm the collectability of accounts receivable given the $275,000 allowance for anticipated returns.